N/A
N=33
Reducing Particulate Matter-associated Cardiovascular Health Effects for Seniors
Cardiometabolic Health
Bottom Line
View on ClinicalTrials.gov: NCT04103346 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Systolic Blood Pressure — 127.0; 126.5 mm Hg — p=0.588
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- air filtration with air purifier with hepa filter (Other); sham (Other)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Systolic Blood Pressure |
127.0; 126.5 | 0.588 |
| SECONDARY Diastolic Blood Pressure |
75.1; 75.3 | 0.748 |
| SECONDARY Atmospheric Particulate Matter (pm2.5) - Indoor |
1.3; 8.3 | <0.001 sig |
| SECONDARY Atmospheric Particulate Matter (pm2.5) - Outdoor |
10.3; 8.9 | 0.0764 |
| SECONDARY 24-hr Personal PM2.5 (Filter-gravimetric Mass) |
5.1; 12.4 | <0.001 sig |
| SECONDARY Black Carbon, Hourly Personal PM2.5 Levels |
— | — |
| SECONDARY Aortic Hemodynamics |
— | — |
| SECONDARY Insulin Sensitivity |
— | — |
| SECONDARY Adrenal Steroid Panel |
— | — |
Summary
Exposure to fine particulate matter (PM2.5) air pollution is an established risk factor for cardiovascular (CV) morbidity.
Eligibility Criteria
Inclusion Criteria
- Nonsmoker
- ≥60 years old
- residing in Carpenter Place Apartments
Exclusion Criteria
- Active cigarette smoker
- daily secondhand smoke exposure (self-report)
- any CV event (myocardial infarction, stroke, heart failure, revascularization) in the past 3 months
- unstable CV condition or risk factor (uncontrolled diabetes, class 3-4 angina or heart failure) or any medical condition that would place the participant at risk from participation or jeopardize study integrity (per investigators)
- expected overnight travel outside their apartment during the 14-week study period
- unable to provide informed consent
- lung disease requiring oxygen
- renal dialysis
- cancer receiving active treatment or chemotherapy
- severe uncontrolled high BP ≥160/100 mm Hg or SBP<115 mm Hg.
- CV medication change in the prior month. If participants are on medications for high BP, diabetes, or a CV condition, they will need to have stable therapy during the prior month with no planned changes during the study period.
Data sourced from ClinicalTrials.gov (NCT04103346). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.